BIOMAT Database Logo BIOMAT Database Logo

[Prolonged survival in patients with progressive multifocal leukoencephalopathy associated with AIDS treated with high doses of zidovudine]. 1994

I Martín-Suárez, and M Aguayo Canela, and D Merińo Muñoz, and E Pujol de la Llave

UI MeSH Term Description Entries
D007968 Leukoencephalopathy, Progressive Multifocal An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus (JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. (From Joynt, Clinical Neurology, 1996, Ch26, pp36-7) Encephalitis, JC Polyomavirus,Progressive Multifocal Leukoencephalopathy,JC Polyomavirus Encephalopathy,Encephalopathies, JC Polyomavirus,Encephalopathy, JC Polyomavirus,JC Polyomavirus Encephalitis,Leukoencephalopathies, Progressive Multifocal,Multifocal Leukoencephalopathies, Progressive,Multifocal Leukoencephalopathy, Progressive,Progressive Multifocal Leukoencephalopathies
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival

Related Publications

I Martín-Suárez, and M Aguayo Canela, and D Merińo Muñoz, and E Pujol de la Llave
Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy.
July 1988, Neurology,
I Martín-Suárez, and M Aguayo Canela, and D Merińo Muñoz, and E Pujol de la Llave
Prolonged survival of a patient with AIDS and progressive multifocal leukoencephalopathy.
May 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
I Martín-Suárez, and M Aguayo Canela, and D Merińo Muñoz, and E Pujol de la Llave
AIDS presenting as progressive multifocal leukoencephalopathy with clinical response to zidovudine.
December 1994, Acta neurologica Scandinavica,
I Martín-Suárez, and M Aguayo Canela, and D Merińo Muñoz, and E Pujol de la Llave
Progressive multifocal leukoencephalopathy associated with prolonged hemodialysis treatment.
January 1984, Virchows Archiv. A, Pathological anatomy and histopathology,
I Martín-Suárez, and M Aguayo Canela, and D Merińo Muñoz, and E Pujol de la Llave
Progressive multifocal leukoencephalopathy: prolonged survival in patients treated with protease inhibitors and cidofovir: a case series.
March 2006, AIDS (London, England),
I Martín-Suárez, and M Aguayo Canela, and D Merińo Muñoz, and E Pujol de la Llave
Cidofovir in combination with HAART and survival in AIDS-associated progressive multifocal leukoencephalopathy.
April 2008, Journal of neurology,
I Martín-Suárez, and M Aguayo Canela, and D Merińo Muñoz, and E Pujol de la Llave
[The inefficacy of zidovudine (AZT) in progressive multifocal leukoencephalopathy (PML) associated with the acquired immunodeficiency syndrome (AIDS)].
November 1990, Revista clinica espanola,
I Martín-Suárez, and M Aguayo Canela, and D Merińo Muñoz, and E Pujol de la Llave
[Progressive multifocal leukoencephalopathy in AIDS].
March 1992, Nederlands tijdschrift voor geneeskunde,
I Martín-Suárez, and M Aguayo Canela, and D Merińo Muñoz, and E Pujol de la Llave
Progressive multifocal leukoencephalopathy in AIDS.
August 1991, AIDS (London, England),
I Martín-Suárez, and M Aguayo Canela, and D Merińo Muñoz, and E Pujol de la Llave
Progressive multifocal leukoencephalopathy in AIDS.
July 1990, JAMA,
Copied contents to your clipboard!